VideaHealth has a substantial distribution advantage: its technology is embedded in software that dental practices already use. That can remove a real obstacle to adoption. It also makes it easier for a purchasing decision to arrive disguised as a software upgrade.
For this third Bench Test, I want to separate the convenience of that arrangement from the clinical evidence, the cost, and the rights attached to the data.
This is a review of public evidence and product documentation, checked September 20, 2026. It is not a hands-on trial or a claim that we independently reproduced the vendor's results.
The five-line scorecard
Line | What the record supports |
|---|---|
Evidence | FDA records document Videa Dental AI clearance K251002, dated September 19, 2025. Its authorized uses have indication-specific age and image limits. Clearance is not a blanket endorsement of every feature in the commercial platform. FDA record. |
Workflow fit | Henry Schein One documents Videa-powered Detect AI within Dentrix and Dentrix Ascend. Confirm the exact module, software version, imaging setup, and subscription in your own office. Henry Schein One announcement. |
Unit economics | A current, comparable public price was not established in this review. Request a written quote covering the required modules, implementation, training, renewal, and cancellation. No estimated vendor price is used in the calculations below. |
Data terms | The public policy covers linked websites, applications, and services. It does not establish the complete negotiated rights for a practice's clinical records. Obtain the applicable agreement, business associate agreement, and data-processing terms. Videa privacy policy. |
Verdict | A reasonable candidate for a measured pilot, particularly when the integration fits the existing practice. The purchasing decision still depends on local performance, full cost, and the actual contract. |
Read the clearance at the level of the finding
The K251002 summary describes an adjunct to professional review. It says the system should not replace a full patient evaluation or be solely relied upon to make or confirm a diagnosis. The scope varies by finding, patient age, and image type; the document limits panoramic uses to historical treatment and normal-anatomy identification.
That matters when a demonstration moves quickly between colorful outputs. Ask which specific cleared function produced each finding and which functions are educational. Videa's own Clinical Assist page labels Patient View as an education feature that is not FDA-cleared.
The practical question is whether the tool helps the clinician reach and explain a sound conclusion. Counting additional flags or additional accepted treatment does not answer that question by itself.
A large rollout answers a different question
In February 2026, Videa and Aspen announced deployment across more than 1,100 offices in six weeks. Their release also reported a 12% increase in treatment acceptance in pilot offices. Those are company-reported implementation and commercial results. Read the announcement.
The deployment is relevant to an operator evaluating implementation capacity. The pilot's treatment-acceptance figure cannot, on its own, establish better patient outcomes, appropriate treatment, or the return a different practice will earn.
A small practice should ask for references with comparable staffing, imaging equipment, software, and patient mix. A large buyer should ask for the distribution of results across offices, including the sites where adoption was difficult.
Put the quote into your own ledger
Here is an illustration, not a Videa quote: a $500 monthly subscription costs $6,000 a year. Spread over 1,600 annual chair-hours, that is $3.75 per chair-hour before implementation and other costs. Dividing by chair-hours makes a cost easier to compare; it does not turn it into a return.
For the return, record what actually changes: paid administrative time, duplicate work, clinician review time, and collections after the additional costs of delivering care. Avoid treating more proposed treatment as collected revenue or a new subscription as proof of clinical improvement.
Agree on the baseline and the pilot's success criteria before the demonstration. Include the time spent reviewing and correcting the AI's output. Those minutes belong in the calculation too.
The contract needs to answer what the policy does not
Videa's public privacy policy is broader than a marketing-site notice: it expressly includes related applications and services displaying the policy. It describes product improvement and retention for several purposes. Reading that language does not tell us every permitted use of patient images under a particular clinical contract.
I would request written answers about clinical-data ownership, model training, subprocessors, retention, export, deletion, and what survives termination. Ask which document controls if the provisions differ. A missing public answer is a due-diligence item; it is not proof that a contractual protection is absent.
What I would do next
Solo practice: pilot the exact product and integration being quoted. Measure the review burden and the usefulness of the patient explanation before accepting a long commitment.
Small group: include offices with different workflows and experience levels. An average result can hide a poor fit at one location.
DSO: separate implementation success, commercial outcomes, and clinical quality. Give each a measure and an accountable reviewer.
Videa's integration is a reason to look closely. A defensible purchase still needs evidence from the practice that will pay for it.
Next: Bench Test #4 examines Overjet Voice, where the record begins with a microphone.
For the clinical side of the discussion, visit OVN Nexus for dentists.
Have experience with this system? Reply with what worked, what required correction, and what you would ask before renewing. Please leave out patient details.